articleHepatologyMar 25, 2016BRONZE OA

Metallothionein‐1G facilitates sorafenib resistance through inhibition of ferroptosis

XSXiaofang SunXNXiaohua NiuRCRuochan ChenWHWenyin HeDCDe Chen

Third Affiliated Hospital of Guangzhou Medical University · Guangzhou Medical University · +1 more institution

PubMed
Indexed incrossrefpubmed

Abstract

UNLABELLED: Hepatocellular carcinoma (HCC) is a major cause of cancer-related death worldwide and currently has the fastest rising incidence of all cancers. Sorafenib was originally identified as an inhibitor of multiple oncogenic kinases and remains the only approved systemic therapy for advanced HCC. However, acquired resistance to sorafenib has been found in HCC patients, which results in poor prognosis. Here, we show that metallothionein (MT)-1G is a critical regulator and promising therapeutic target of sorafenib resistance in human HCC cells. The expression of MT-1G messenger RNA and protein is remarkably induced by sorafenib but not other clinically relevant kinase inhibitors (e.g., erlotinib,…

Citation impact

731
total citations
FWCI
22.11
Percentile
100%
References
49
Citations per year

Authors

7

Topics & keywords

Topics
Keywords
  • Sorafenib
  • Cancer research
  • Gefitinib
  • Gene knockdown
  • Pharmacology
  • Medicine
  • Hepatocellular carcinoma
  • Cancer
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding